Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Carcinoma, Ovarian Epithelial 4 Carcinoma 4 Stomach Neoplasms 3 Peritoneal Neoplasms 3 Neoplasms 3 Fallopian Tube Neoplasms 3 Urinary Bladder Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Glandular and Epithelial 1 EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1 Ascites 1 Adenocarcinoma 1

Interventions

Oxaliplatin 46 Gemcitabine 45 Fluorouracil 40 Capecitabine 31 pembrolizumab 29 Leucovorin 29 Docetaxel 27 Cisplatin 25 Paclitaxel 23 Irinotecan 18 Carboplatin 18 Bevacizumab 18 130-nm albumin-bound paclitaxel 17 Pemetrexed 15 Albumin-Bound Paclitaxel 15 Radiotherapy 14 Nivolumab 12 Ramucirumab 11 Cyclophosphamide 11 Trastuzumab 8 Erlotinib Hydrochloride 8 Taxes 7 Radiosurgery 7 Drug Therapy 7 cemiplimab 6 zolbetuximab 5 trastuzumab deruxtecan 5 regorafenib 5 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × catumaxomab × Clear all

NCT01504256 2018-01-23

CatuNeo

AIO-Studien-gGmbH

Phase 2 Completed

Adenocarcinoma, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡